Skip to content

Study · Randomized controlled trial · n = 32 · 1996

7 results

Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial.

Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A

Annals of internal medicine1 Dec 1996Cited by 160 (Europe PMC)

PMID8967668 (opens in a new tab)DOI10.7326/0003-4819-125-11-199612010-00003 (opens in a new tab)PepBankPUB-08967668
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In men with adult-onset GH deficiency, GH increased lumbar spine bone mineral density by 5.1% +/- 4.1%, significantly versus placebo (P < 0.01).

    In plain wordsIn men with adult-onset GH deficiency, GH increased lumbar spine bone density more than placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLumbar spine bone mineral density
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initial daily dose 10 micrograms/kg, reduced by 25% if IGF-1 elevated · 18 monthsAs given in this study (human).

    Measurements

    Change in lumbar spine bone mineral density
    5.1%
    growth hormone group, mean change

    Source sentences

    Summary
    Growth hormone therapy increased bone mineral density in the lumbar spine by a mean (+/- SD) of 5.1% +/- 4.1% and bone mineral density in the femoral neck by 2.4% +/- 3.5%.
    5 context sentences
    Summary · context
    These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons).
    Summary · context
    Randomized, placebo-controlled study.
    Summary · context
    32 men with adult-onset growth hormone deficiency.
    Summary · context
    Growth hormone (initial daily dose, 10 micrograms/kg of body weight) or placebo for 18 months.
    Summary · context
    The growth hormone dose was reduced by 25% if IGF-1 levels were elevated.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with adult-onset GH deficiency, GH increased femoral neck bone mineral density by 2.4% +/- 3.5%, significantly versus placebo (P < 0.01).

    In plain wordsIn men with adult-onset GH deficiency, GH increased femoral neck bone density more than placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseFemoral neck bone mineral density
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initial daily dose 10 micrograms/kg, reduced by 25% if IGF-1 elevated · 18 monthsAs given in this study (human).

    Measurements

    Change in femoral neck bone mineral density
    2.4%
    growth hormone group, mean change

    Source sentences

    Summary
    Growth hormone therapy increased bone mineral density in the lumbar spine by a mean (+/- SD) of 5.1% +/- 4.1% and bone mineral density in the femoral neck by 2.4% +/- 3.5%.
    5 context sentences
    Summary · context
    These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons).
    Summary · context
    Randomized, placebo-controlled study.
    Summary · context
    32 men with adult-onset growth hormone deficiency.
    Summary · context
    Growth hormone (initial daily dose, 10 micrograms/kg of body weight) or placebo for 18 months.
    Summary · context
    The growth hormone dose was reduced by 25% if IGF-1 levels were elevated.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with adult-onset GH deficiency, GH increased osteocalcin from 4.4 +/- 3.6 to 7.2 +/- 4.6 mg/L, significantly versus placebo (P < 0.01).

    In plain wordsIn men with adult-onset GH deficiency, GH increased osteocalcin more than placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseOsteocalcin
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initial daily dose 10 micrograms/kg, reduced by 25% if IGF-1 elevated · First 12 monthsAs given in this study (human).

    Measurements

    Osteocalcin
    4.4 mg/L
    growth hormone group, baseline
    Osteocalcin
    7.2 mg/L
    growth hormone group, follow-up value

    Source sentences

    Summary
    In the growth hormone group, significant increases were seen in the following markers of bone turnover: osteocalcin (4.4 +/- 3.6 mg/L to 7.2 +/- 4.6 mg/L) and urinary pyridinoline (39.0 +/- 19.8 nmol/mmol of creatinine to 55.7 +/- 25.5 nmol/mmol of creatinine) and deoxypyridinoline (8.4 +/- 7.1 nmol…
    5 context sentences
    Summary · context
    These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons).
    Summary · context
    Randomized, placebo-controlled study.
    Summary · context
    32 men with adult-onset growth hormone deficiency.
    Summary · context
    Growth hormone (initial daily dose, 10 micrograms/kg of body weight) or placebo for 18 months.
    Summary · context
    The growth hormone dose was reduced by 25% if IGF-1 levels were elevated.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In men with adult-onset GH deficiency, GH increased urinary pyridinoline from 39.0 +/- 19.8 to 55.7 +/- 25.5 nmol/mmol of creatinine (P < 0.01 versus placebo).

    In plain wordsIn men with adult-onset GH deficiency, GH increased urinary pyridinoline more than placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseUrinary pyridinoline
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initial daily dose 10 micrograms/kg, reduced by 25% if IGF-1 elevated · First 12 monthsAs given in this study (human).

    Measurements

    Urinary pyridinoline
    39 nmol/mmol of creatinine
    growth hormone group, baseline
    Urinary pyridinoline
    55.7 nmol/mmol of creatinine
    growth hormone group, follow-up value

    Source sentences

    Summary
    In the growth hormone group, significant increases were seen in the following markers of bone turnover: osteocalcin (4.4 +/- 3.6 mg/L to 7.2 +/- 4.6 mg/L) and urinary pyridinoline (39.0 +/- 19.8 nmol/mmol of creatinine to 55.7 +/- 25.5 nmol/mmol of creatinine) and deoxypyridinoline (8.4 +/- 7.1 nmol…
    5 context sentences
    Summary · context
    These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons).
    Summary · context
    Randomized, placebo-controlled study.
    Summary · context
    32 men with adult-onset growth hormone deficiency.
    Summary · context
    Growth hormone (initial daily dose, 10 micrograms/kg of body weight) or placebo for 18 months.
    Summary · context
    The growth hormone dose was reduced by 25% if IGF-1 levels were elevated.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In men with adult-onset GH deficiency, GH increased urinary deoxypyridinoline from 8.4 +/- 7.1 to 14.9 +/- 9.4 nmol/mmol of creatinine (P < 0.01 versus placebo).

    In plain wordsIn men with adult-onset GH deficiency, GH increased urinary deoxypyridinoline more than placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseUrinary deoxypyridinoline
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Initial daily dose 10 micrograms/kg, reduced by 25% if IGF-1 elevated · First 12 monthsAs given in this study (human).

    Measurements

    Urinary deoxypyridinoline
    8.4 nmol/mmol of creatinine
    growth hormone group, baseline
    Urinary deoxypyridinoline
    14.9 nmol/mmol of creatinine
    growth hormone group, follow-up value

    Source sentences

    Summary
    In the growth hormone group, significant increases were seen in the following markers of bone turnover: osteocalcin (4.4 +/- 3.6 mg/L to 7.2 +/- 4.6 mg/L) and urinary pyridinoline (39.0 +/- 19.8 nmol/mmol of creatinine to 55.7 +/- 25.5 nmol/mmol of creatinine) and deoxypyridinoline (8.4 +/- 7.1 nmol…
    5 context sentences
    Summary · context
    These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons).
    Summary · context
    Randomized, placebo-controlled study.
    Summary · context
    32 men with adult-onset growth hormone deficiency.
    Summary · context
    Growth hormone (initial daily dose, 10 micrograms/kg of body weight) or placebo for 18 months.
    Summary · context
    The growth hormone dose was reduced by 25% if IGF-1 levels were elevated.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In men with adult-onset GH deficiency, GH reduced body fat from 31.9% +/- 6.5% to 28.3% +/- 7.0% (P < 0.01 versus placebo).

    In plain wordsIn men with adult-onset GH deficiency, GH reduced percentage body fat more than placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreasePercentage body fat
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Initial daily dose 10 micrograms/kg, reduced by 25% if IGF-1 elevated · 18 monthsAs given in this study (human).

    Measurements

    Percentage body fat
    31.9%
    growth hormone group, baseline
    Percentage body fat
    28.3%
    growth hormone group, follow-up value

    Source sentences

    Summary
    Percentage of body fat in the growth hormone group decreased (from 31.9% +/- 6.5% to 28.3% +/- 7.0%), and lean body mass increased (from 59.0 +/- 8.5 kg to 61.5 +/- 6.9 kg).
    5 context sentences
    Summary · context
    These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons).
    Summary · context
    Randomized, placebo-controlled study.
    Summary · context
    32 men with adult-onset growth hormone deficiency.
    Summary · context
    Growth hormone (initial daily dose, 10 micrograms/kg of body weight) or placebo for 18 months.
    Summary · context
    The growth hormone dose was reduced by 25% if IGF-1 levels were elevated.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In men with adult-onset GH deficiency, GH increased lean body mass from 59.0 +/- 8.5 to 61.5 +/- 6.9 kg (P < 0.01 versus placebo).

    In plain wordsIn men with adult-onset GH deficiency, GH increased lean body mass more than placebo.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLean body mass
    Study

    n = 32

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Initial daily dose 10 micrograms/kg, reduced by 25% if IGF-1 elevated · 18 monthsAs given in this study (human).

    Measurements

    Lean body mass
    59 kg
    growth hormone group, baseline
    Lean body mass
    61.5 kg
    growth hormone group, follow-up value

    Source sentences

    Summary
    Percentage of body fat in the growth hormone group decreased (from 31.9% +/- 6.5% to 28.3% +/- 7.0%), and lean body mass increased (from 59.0 +/- 8.5 kg to 61.5 +/- 6.9 kg).
    5 context sentences
    Summary · context
    These changes were significant compared with corresponding changes in the placebo group (P < 0.01 for all comparisons).
    Summary · context
    Randomized, placebo-controlled study.
    Summary · context
    32 men with adult-onset growth hormone deficiency.
    Summary · context
    Growth hormone (initial daily dose, 10 micrograms/kg of body weight) or placebo for 18 months.
    Summary · context
    The growth hormone dose was reduced by 25% if IGF-1 levels were elevated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT00136032

Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women

Massachusetts General Hospitaln = 63Jan 2002 to Nov 2006

Growth Hormone Deficiency

Trial pageClinicalTrials.govUpdated 18 Feb 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.